137 related articles for article (PubMed ID: 35304738)
1. Therapy-related myeloid neoplasms with normal karyotype show distinct genomic and clinical characteristics compared to their counterparts with abnormal karyotype.
Tariq H; Barnea Slonim L; Coty Fattal Z; Alikhan MB; Segal J; Gurbuxani S; Helenowski IB; Zhang H; Sukhanova M; Lu X; Altman JK; Chen QC; Behdad A
Br J Haematol; 2022 Jun; 197(6):736-744. PubMed ID: 35304738
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic and Molecular Analysis of Normal Karyotype Therapy-Related and De Novo Acute Myeloid Leukemia: A Multi-Institutional Study by the Bone Marrow Pathology Group.
Cantu MD; Kanagal-Shamanna R; Wang SA; Kadia T; Bueso-Ramos CE; Patel SS; Geyer JT; Tam W; Madanat Y; Li P; George TI; Nichols MM; Rogers HJ; Liu YC; Aggarwal N; Kurzer JH; Maracaja DLV; Hsi ED; Zaiem F; Babu D; Foucar K; Laczko D; Bagg A; Orazi A; Arber DA; Hasserjian RP; Weinberg OK
JCO Precis Oncol; 2023 Jan; 7():e2200400. PubMed ID: 36689697
[TBL] [Abstract][Full Text] [Related]
3. Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup.
Hong M; Hao S; Patel KP; Kantarjian HM; Garcia-Manero G; Yin CC; Medeiros LJ; Lin P; Lu X
Cancer Genet; 2016 May; 209(5):205-14. PubMed ID: 27134073
[TBL] [Abstract][Full Text] [Related]
4. ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype.
Prats-Martín C; Burillo-Sanz S; Morales-Camacho RM; Pérez-López O; Suito M; Vargas MT; Caballero-Velázquez T; Carrillo-Cruz E; González J; Bernal R; Pérez-Simón JA
Cancer Med; 2020 Jun; 9(11):3637-3646. PubMed ID: 32216059
[TBL] [Abstract][Full Text] [Related]
5. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.
Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Peng J; Tang G; Goswami M; Young KH; Singh R; Medeiros LJ; Kantarjian HM; Luthra R; Wang SA
J Hematol Oncol; 2015 May; 8():45. PubMed ID: 25952993
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of cytogenetic and molecular genetic abnormalities in 634 Chinese patients with myelodysplastic syndromes.
Yan X; Wang L; Jiang L; Luo Y; Lin P; Yang W; Ren Y; Ma L; Zhou X; Mei C; Ye L; Xu G; Xu W; Yang H; Lu C; Jin J; Tong H
Cancer Med; 2021 Mar; 10(5):1759-1771. PubMed ID: 33609081
[TBL] [Abstract][Full Text] [Related]
7. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.
Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Fu B; Tang G; Goswami M; Singh R; Kanagal-Shamanna R; Pierce SA; Young KH; Kantarjian HM; Medeiros LJ; Luthra R; Wang SA
Leuk Res; 2015 Mar; 39(3):348-54. PubMed ID: 25573287
[TBL] [Abstract][Full Text] [Related]
8. What Is Abnormal in Normal Karyotype Acute Myeloid Leukemia in Children? Analysis of the Mutational Landscape and Prognosis of the TARGET-AML Cohort.
Herlin MK; Yones SA; Kjeldsen E; Holmfeldt L; Hasle H
Genes (Basel); 2021 May; 12(6):. PubMed ID: 34064268
[TBL] [Abstract][Full Text] [Related]
9. Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study.
Kayser S; Hills RK; Langova R; Kramer M; Guijarro F; Sustkova Z; Estey EH; Shaw CM; Ráčil Z; Mayer J; Zak P; Baer MR; Brunner AM; Szotkowski T; Cetkovsky P; Grimwade D; Walter RB; Burnett AK; Ho AD; Ehninger G; Müller-Tidow C; Platzbecker U; Thiede C; Röllig C; Schulz A; Warsow G; Brors B; Esteve J; Russell NH; Schlenk RF; Levis MJ
Br J Haematol; 2021 Mar; 192(5):832-842. PubMed ID: 33529373
[TBL] [Abstract][Full Text] [Related]
10. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.
Devillier R; Mansat-De Mas V; Gelsi-Boyer V; Demur C; Murati A; Corre J; Prebet T; Bertoli S; Brecqueville M; Arnoulet C; Recher C; Vey N; Mozziconacci MJ; Delabesse E; Birnbaum D
Oncotarget; 2015 Apr; 6(10):8388-96. PubMed ID: 25860933
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic Features of Therapy-Related Myeloid Neoplasms in Patients with Myeloma in the Era of Novel Therapies.
Jelloul FZ; Quesada AE; Yang RK; Li S; Wang W; Xu J; Tang G; Yin CC; Fang H; El Hussein S; Khoury J; Bassett RL; Garcia-Manero G; Manasanch EE; Orlowski RZ; Qazilbash MH; Patel KP; Medeiros LJ; Lin P
Mod Pathol; 2023 Jun; 36(6):100166. PubMed ID: 36990279
[TBL] [Abstract][Full Text] [Related]
12. [Mutation analysis of 77 patients with normal-karyotype myelodysplastic syndrome].
Qin W; Chen M; Cai X; Chao H; Liu J; Jiang N; Zhou M; Lu X; Chen S; Zhang R; He C; Wang Q
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2019 Sep; 36(9):857-861. PubMed ID: 31515775
[TBL] [Abstract][Full Text] [Related]
13. The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution.
Singhal D; Wee LYA; Kutyna MM; Chhetri R; Geoghegan J; Schreiber AW; Feng J; Wang PP; Babic M; Parker WT; Hiwase S; Edwards S; Moore S; Branford S; Kuzmanovic T; Singhal N; Gowda R; Brown AL; Arts P; To LB; Bardy PG; Lewis ID; D'Andrea RJ; Maciejewski JP; Scott HS; Hahn CN; Hiwase DK
Leukemia; 2019 Dec; 33(12):2842-2853. PubMed ID: 31089247
[TBL] [Abstract][Full Text] [Related]
14. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study.
Rogers HJ; Vardiman JW; Anastasi J; Raca G; Savage NM; Cherry AM; Arber D; Moore E; Morrissette JJ; Bagg A; Liu YC; Mathew S; Orazi A; Lin P; Wang SA; Bueso-Ramos CE; Foucar K; Hasserjian RP; Tiu RV; Karafa M; Hsi ED
Haematologica; 2014 May; 99(5):821-9. PubMed ID: 24463215
[TBL] [Abstract][Full Text] [Related]
15. Mutational landscape of patients with acute myeloid leukemia or myelodysplastic syndromes in the context of RUNX1 mutation.
Wang K; Zhou F; Cai X; Chao H; Zhang R; Chen S
Hematology; 2020 Dec; 25(1):211-218. PubMed ID: 32476595
[No Abstract] [Full Text] [Related]
16. Genomic, immunophenotypic, and NPM1/FLT3 mutational studies on 17 patients with normal karyotype acute myeloid leukemia (AML) followed by aberrant karyotype AML at relapse.
Wang ES; Sait SN; Gold D; Mashtare T; Starostik P; Ford LA; Wetzler M; Nowak NJ; Deeb G
Cancer Genet Cytogenet; 2010 Oct; 202(2):101-7. PubMed ID: 20875872
[TBL] [Abstract][Full Text] [Related]
17. [Allo-HSCT for acute myeloid leukemia with myelodysplastic-related changes: a clinical analysis].
Zhang HX; Pang AM; Chen X; Zhang RL; Zhai WH; Ma QL; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):814-822. PubMed ID: 34788920
[No Abstract] [Full Text] [Related]
18. Double minute chromosomes in acute myeloid leukemia and myelodysplastic syndromes are associated with complex karyotype, monosomal karyotype,
Wang N; Yuan L; Jing Y; Fan K; Jin H; Lv C; Wang L; Yu L
Leuk Lymphoma; 2021 Oct; 62(10):2466-2474. PubMed ID: 33904352
[TBL] [Abstract][Full Text] [Related]
19. [Clinical analysis of gene mutation characteristics and mutation burden in myelodysplastic syndrome].
Lü XD; Li YW; Guo Z; Xin YP; Hu JY; Fan RH; Song YP
Zhonghua Yi Xue Za Zhi; 2020 Mar; 100(12):933-937. PubMed ID: 32234169
[No Abstract] [Full Text] [Related]
20. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.
Volkert S; Kohlmann A; Schnittger S; Kern W; Haferlach T; Haferlach C
Genes Chromosomes Cancer; 2014 May; 53(5):402-10. PubMed ID: 24493299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
